HemaSphere最新文献

{"title":"Working towards harmonization of clinical trial reporting in Hodgkin lymphoma.","authors":"Carsten Kobe, Philippe Armand, Sven Borchmann, Graham P Collins, Anne-Segolene Cottereau, Justin Ferdinandus, Alex F Herrera, Davide Rossi, Wouter J Plattel, Sally F Barrington, Martin Hutchings","doi":"10.1002/hem3.70196","DOIUrl":"10.1002/hem3.70196","url":null,"abstract":"","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"9 8","pages":"e70196"},"PeriodicalIF":14.6,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12331867/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Harnessing the immunotherapeutic potentials of gamma delta T cells against hematological malignancies.","authors":"Charles Agbuduwe, John Maher, John Anderson","doi":"10.1002/hem3.70182","DOIUrl":"10.1002/hem3.70182","url":null,"abstract":"<p><p>Gamma delta (γδ) T cells, which constitute about 5%-10% of peripheral blood lymphocytes, play key roles in tumor immunosurveillance and are often enriched within epithelial tissues. They are unique in their Major Histocompatibility Complex-independent antigen recognition via the γδ T-cell receptor (TCR) as well as via innate receptors, making them ideal1 candidates for allogeneic \"off-the-shelf\" cell therapy products. In humans, two main structural subsets of γδ T cells-Vδ1 and Vδ2-have been defined, which differ in TCRδ chains, effector function, and tissue localizations. Vδ2 T cells constitute the majority of γδ T cells in peripheral blood and can be expanded with aminobisphosphonates such as zoledronic acid. In recent years, the potent antitumor functions of Vδ1 T cells have also been recognized, and new expansion protocols are being developed. Given the ample preclinical evidence of γδ T-cell efficacy against hematological malignancies, several γδ T-cell-based cell therapy products are currently in clinical development, and there has been an exponential increase in the number of adoptive γδ T-cell therapy clinical trials. This comprehensive review provides an overview of the rationale for γδ T-cell therapy, ongoing clinical trials, as well as the challenges and future role of γδ T-cell-based immune therapies in hematology.</p>","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"9 8","pages":"e70182"},"PeriodicalIF":14.6,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12331877/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cell surface surprise: NPM1 is an immune therapy target for acute myeloid leukemia.","authors":"Hansen J Kosasih, Charles E de Bock","doi":"10.1002/hem3.70193","DOIUrl":"10.1002/hem3.70193","url":null,"abstract":"","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"9 8","pages":"e70193"},"PeriodicalIF":14.6,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12331875/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Know your blood: Addressing barriers to preconceptual screening for sickle cell disease.","authors":"Ernel Boadi, Alidor Gaspar, Stephen P Hibbs","doi":"10.1002/hem3.70194","DOIUrl":"10.1002/hem3.70194","url":null,"abstract":"","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"9 8","pages":"e70194"},"PeriodicalIF":14.6,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12331872/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ex vivo drug responses and molecular profiles of 597 pediatric acute lymphoblastic leukemia patients","authors":"Anna Pia Enblad,&nbsp;Olga Krali,&nbsp;Henrik Gezelius,&nbsp;Anders Lundmark,&nbsp;Kristin Blom,&nbsp;Claes Andersson,&nbsp;Josefine Palle,&nbsp;Britt-Marie Frost,&nbsp;Samppa Ryhänen,&nbsp;Trond Flægstad,&nbsp;Ólafur G. Jónsson,&nbsp;Kjeld Schmiegelow,&nbsp;Mats Heyman,&nbsp;Arja Harila,&nbsp;Peter Nygren,&nbsp;Rolf Larsson,&nbsp;Gudmar Lönnerholm,&nbsp;Jessica Nordlund","doi":"10.1002/hem3.70176","DOIUrl":"https://doi.org/10.1002/hem3.70176","url":null,"abstract":"<p>Ex vivo drug response profiling is emerging as a valuable tool for identifying drug resistance mechanisms and advancing precision medicine in hematological cancers. However, the functional impact of dysregulation of the epigenome and transcriptome in this context remains poorly understood. In this study, we combined ex vivo drug sensitivity profiling with transcriptomic and epigenomic analyses in diagnostic samples from 597 pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients. Ex vivo resistance to antimetabolites (e.g., cytarabine, thioguanine), glucocorticoids (e.g., dexamethasone, prednisolone), and doxorubicin was independently associated with reduced relapse-free survival (P &lt; 0.05). Molecular profiling identified pretreatment DNA methylation and gene expression patterns distinguishing resistant from sensitive cases, revealing key drug resistance signatures. These included aberrant expression of genes related to heme metabolism (e.g., <i>ATPV06A</i>) and <i>KRAS</i> signaling (e.g., <i>GS02</i>). Notably, we also observed atypical expression of genes usually restricted to T cells and other immune cells (e.g., <i>ITK</i>) in resistant BCP-ALL cells. Our findings demonstrate that ex vivo drug response patterns are predictive of clinical outcomes and reflect intrinsic molecular states associated with drug tolerance. This integrative multi-omics approach highlights potential therapeutic targets and underscores the value of functional precision medicine in identifying treatment vulnerabilities in pediatric ALL.</p>","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"9 7","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hem3.70176","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144714824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Quality of vitamin K antagonist treatment during the last year of life”","authors":"","doi":"10.1002/hem3.70173","DOIUrl":"https://doi.org/10.1002/hem3.70173","url":null,"abstract":"<p>Visser C, Kempers EK, Goedegebuur J, et al. Quality of vitamin K antagonist treatment during the last year of life. <i>HemaSphere</i>. 2025;9(5):e70135. https://doi.org/10.1002/hem3.70135.</p><p>In the author listing of the manuscript, the name of an author was incorrectly listed as Jamilla Goedgebuur. The correct name is Jamilla Goedegebuur.</p><p>The original publication has been corrected. We apologize for this error.</p>","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"9 7","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hem3.70173","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144714825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Open or closed? Understanding the molecular mechanisms and clinical implications of ADAMTS13's conformation","authors":"Quintijn Bonnez,&nbsp;Karen Vanhoorelbeke","doi":"10.1002/hem3.70189","DOIUrl":"https://doi.org/10.1002/hem3.70189","url":null,"abstract":"<p>By proteolyzing prothrombotic von Willebrand factor (VWF) multimers, ADAMTS13 (A Disintegrin And Metalloproteinase with ThromboSpondin type-1 repeats, member 13) ensures balanced hemostasis and prevents microvascular thrombosis. ADAMTS13's conformational regulation is not only crucial for its enzymatic function, but also for the pathophysiology of thrombotic thrombocytopenic purpura (TTP). In the first part of this review, the unique structural features that keep ADAMTS13 in its closed, latent conformation are explored. Moreover, the recent structure predictions that propose a compactly folded model for closed ADAMTS13, and the molecular mechanisms involved in ADAMTS13's opening by its VWF substrate and other allosteric activators are discussed. Over the last decade, the changes in ADAMTS13's conformation in the context of immune-mediated TTP (iTTP) were increasingly characterized, with open ADAMTS13 having emerged as a novel specific biomarker for acute and subclinical iTTP. Furthermore, open ADAMTS13 is gaining clinical attention to improve the prediction of early relapses during follow-up of iTTP patients in remission. The specificity of the open ADAMTS13 biomarker for iTTP was retrospectively validated in patient cohorts with various thrombotic microangiopathies or hemostatic disorders, all dominantly presenting closed ADAMTS13. Hence, this review summarizes the molecular mechanisms that regulate ADAMTS13's conformation and links these with the clinical implications of ADAMTS13's open and closed conformations.</p>","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"9 7","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hem3.70189","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144712093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clonal hematopoiesis of indeterminate potential (CHIP) and risk of non-Hodgkin lymphoma: A community-based cohort study","authors":"Mingcheng Liu,&nbsp;Luyao Zhou,&nbsp;Qiaoxue Liu,&nbsp;Xiaojing Wang,&nbsp;Hui Wei,&nbsp;Qianwei Liu","doi":"10.1002/hem3.70187","DOIUrl":"https://doi.org/10.1002/hem3.70187","url":null,"abstract":"<p>Clonal hematopoiesis of indeterminate potential (CHIP), characterized by the expansion of hematopoietic cell clones carrying somatic mutations,<span>^{1, 2}</span> is considered as a risk factor for various diseases, especially hematological malignancies.<span>^3-6</span> In contrast to the well-established association between CHIP and myeloid malignancies, large knowledge gaps exist for the association between CHIP and the risk of lymphoid malignancy.<span>⁷</span> Non-Hodgkin lymphoma (NHL) is a heterogeneous group of hematopoietic malignancies and accounts for about 90% of all lymphomas, which arise from the malignant transformation of lymphocytes.<span>⁸</span> Although several factors (e.g., immune disorders, infections, medicines, genetics, and lifestyle) have been suggested as individual risk factors of NHL, a significant proportion of NHL patients cannot be attributed to provoked or known risk factors.<span>⁹</span> Lymphoid CHIP has been revealed to be associated with a higher incidence of lymphoid malignancies;<span>¹⁰</span> however, the majority of CHIP is myeloid, and the relationship between CHIP and NHL remains to be elucidated. Thus, we conducted a large-scale community-based cohort study using data from the UK Biobank and investigated whether CHIP is a risk factor for NHL.</p><p>CHIP was ascertained by analyzing whole-exome sequencing (WES) data. We used the Cox regression model to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) of NHL associated with CHIP. The detailed methods can be seen in the supplementary information, Figure S1, and Table S1. Among the 437,219 participants from the UK Biobank, we identified 13,068 individuals with CHIP and 424,151 without CHIP. The demographic and clinical characteristics of the cohort are summarized in Table S2. Individuals with CHIP were older, with a median age of 62 years, compared to those without CHIP, who had a median age of 57 years. Furthermore, participants with CHIP were more inclined to be male, of White ethnicity, overweight, and have a history of smoking (either previously or currently) compared to those without CHIP. The median follow-up was 12.6 years for individuals without CHIP and 12.8 years for those with CHIP. Among individuals with CHIP, there were 150 incident cases of any NHL (incidence rate [IR], 93.22 per 100,000 person-years), while 2653 cases (IR, 48.35 per 100,000 person-years) were identified among individuals without CHIP (i.e., reference). Individuals with CHIP had a higher risk of any NHL than those in the non-CHIP group (hazard ratio [HR]: 1.52, 95% confidence interval [CI]: 1.30–1.78) (Table 1).</p><p>In the analysis by subtypes of NHL (Table 1), we found heightened risks in relation to CHIP for most studied NHL subtypes, especially for CLL/SLL (HR: 1.64, 95% CI: 1.21–2.21), FL (HR: 1.63, 95% CI: 1.06–2.51), and mature T/NK-cell lymphomas (HR: 2.79, 95% CI: 1.57–4.96). Focusin","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"9 7","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hem3.70187","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144712094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clonal hematopoiesis in AML long-term survivors: Risk factors and clinical consequences","authors":"Simon M. Krauß,&nbsp;Eva Telzerow,&nbsp;Daniel Richter,&nbsp;Anna S. Moret,&nbsp;Maja Rothenberg-Thurley,&nbsp;Cristina Sauerland,&nbsp;Anne Weigert,&nbsp;Alessia Fraccaroli,&nbsp;Johanna Tischer,&nbsp;Frank Ziemann,&nbsp;Katharina S. Götze,&nbsp;Wolfgang E. Berdel,&nbsp;Bernhard Wörmann,&nbsp;Utz Krug,&nbsp;Jan Braess,&nbsp;Pia Heussner,&nbsp;Wolfgang Enard,&nbsp;Wolfgang Hiddemann,&nbsp;Karsten Spiekermann,&nbsp;Dennis Görlich,&nbsp;Uwe Platzbecker,&nbsp;Klaus H. Metzeler","doi":"10.1002/hem3.70183","DOIUrl":"https://doi.org/10.1002/hem3.70183","url":null,"abstract":"<p>Clonal hematopoiesis (CH) is common in the general population and associated with various health risks, but its prevalence and clinical implications in acute myeloid leukemia (AML) long-term survivors (LTS; ≥5-year survival) are unknown. We analyzed CH in 373 AML-LTS with a median 11.6-year follow-up from diagnosis using a sensitive targeted sequencing assay based on single-molecule molecular inversion probes. CH variants were detected in 61.9% of survivors, with 26% having small-clone CH (SC-CH, variant allele frequency (VAF) &lt; 2%) and 35.9% CH of indeterminate potential (≥2% VAF). CH was more prevalent in survivors treated with chemotherapy only (75.7%) compared to those who received allogeneic stem cell transplantation (alloSCT, 54.0%) and to age group-matched healthy controls. In chemotherapy-treated survivors, CH prevalence increased with age, whereas in alloSCT recipients, it most closely associated with hematopoietic age (i.e., the sum of donor age and time since transplantation). The variant spectrum also differed by treatment, with <i>TP53</i> and <i>PPM1D</i> variants being more common in the chemotherapy group. CH variants ≥10% VAF associated with increased risks of diabetes in alloSCT recipients and secondary neoplasms in chemotherapy-treated survivors. This study provides insights into the high prevalence and potential clinical relevance of CH in AML-LTS.</p>","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"9 7","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hem3.70183","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144688115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distribution reappraisal of peripheral T- and NK-cell lymphoma entities through the French Lymphopath network database","authors":"Thomas Grange,&nbsp;Elsa Poullot,&nbsp;Marie Parrens,&nbsp;Alexandra Traverse-Glehen,&nbsp;Charlotte Syrykh,&nbsp;Luc Xerri,&nbsp;Julie Bruneau,&nbsp;Virginie Fataccioli,&nbsp;Nadia Amara,&nbsp;Romain Dubois,&nbsp;Anne Moreau,&nbsp;Alina Nicolae,&nbsp;Fanny Drieux,&nbsp;Vanessa Lacheretz-Szablewski,&nbsp;Francisco Llamas-Gutierrez,&nbsp;Albane Ledoux-Pilon,&nbsp;Marie-Christine Copin,&nbsp;Catherine Chassagne-Clément,&nbsp;François Lemonnier,&nbsp;Pierre Brousset,&nbsp;Philippe Gaulard","doi":"10.1002/hem3.70181","DOIUrl":"https://doi.org/10.1002/hem3.70181","url":null,"abstract":"&lt;p&gt;The French National Cancer Institute-labelled Lymphopath network was established to provide real-time expert histopathological review of every newly diagnosed or suspected lymphoma in France. It is composed of expert hematopathologists working across 31 academic institutions, equipped with comprehensive access to immunohistochemistry, fluorescent in situ hybridization (FISH), clonality analysis, and molecular testing (Figure 1A). In 2017, we reported&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; on a review of 36,920 lymphomas registered between 2010 and 2013, including 2049 noncutaneous peripheral T-cell lymphomas (PTCLs). These diagnoses were established according to the criteria of the 2008 WHO classification of lymphoid neoplasms.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;The 2017 revision of the WHO classification&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; introduced significant changes to the classification of PTCLs, which have been largely upheld in the recently updated WHO and ICC classifications.&lt;span&gt;&lt;sup&gt;4, 5&lt;/sup&gt;&lt;/span&gt; An important change was the recognition of a broad umbrella category of PTCLs derived from T follicular helper cells (TFH)—now referred to as (nodal) TFH lymphomas (TFHL)—encompassing angioimmunoblastic T-cell lymphoma (AITL) (TFHL, angioimmunoblastic-type), follicular T-cell lymphoma (TFHL, follicular type), and nodal PTCL with TFH phenotype (TFHL, not otherwise specified [NOS]). The latter were classified as PTCL, NOS prior to the 2017 classification. TFHLs share expression of TFH-related antigens as well as clinical features and recurrent mutations.&lt;span&gt;&lt;sup&gt;6, 7&lt;/sup&gt;&lt;/span&gt; Another update was the renaming of enteropathy-associated T-cell lymphoma (EATL) type 2 as monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) to reflect its distinct pathological, immunophenotypic, genetic, and clinical characteristics and its lack of association with celiac disease.&lt;span&gt;&lt;sup&gt;8, 9&lt;/sup&gt;&lt;/span&gt; Additionally, two rare entities, indolent T-cell lymphoproliferative disorder of the gastrointestinal tract and breast implant-associated anaplastic large-cell lymphoma (ALCL), were introduced in the 2017 classification. Our study aims to evaluate how these changes have impacted the relative distribution of noncutaneous PTCLs in France.&lt;/p&gt;&lt;p&gt;Data from all noncutaneous lymphomas newly diagnosed between January 2018 and December 2021 were extracted from the Lymphopath database in March 2024. All cases had been classified according to the 2017 WHO classification after expert review by the Lymphopath hematopathologists. Among the 44,035 cases registered, 2331 (5.3%) were considered as PTCL by the referral pathologist, whereas 2751 (6.2%) had a final diagnosis of T-cell lymphoma after expert review. T-cell lymphoblastic lymphomas/acute lymphoblastic leukemias (&lt;i&gt;n&lt;/i&gt; = 220) were excluded from the analysis, resulting in a total of 2529 noncutaneous PTCLs over the 4-year period (Figure 1B). This represents a 23.4% increase in the annual incidence of PTCL registered by the L","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"9 7","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hem3.70181","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144647784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}